ID   LoVo/DR5
AC   CVCL_6C49
DR   cancercelllines; CVCL_6C49
DR   Wikidata; Q54902904
RX   PubMed=1673331;
RX   PubMed=2896069;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0399 ! LoVo
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 23-02-16; Last updated: 05-10-23; Version: 13
//
RX   PubMed=1673331;
RA   Slovak M.L., Coccia M., Meltzer P.S., Trent J.M.;
RT   "Molecular analysis of two human doxorubicin-resistant cell lines:
RT   evidence for differing multidrug resistance mechanisms.";
RL   Anticancer Res. 11:423-428(1991).
//
RX   PubMed=2896069;
RA   Slovak M.L., Hoeltge G.A., Dalton W.S., Trent J.M.;
RT   "Pharmacological and biological evidence for differing mechanisms of
RT   doxorubicin resistance in two human tumor cell lines.";
RL   Cancer Res. 48:2793-2797(1988).
//